scholarly journals Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

2021 ◽  
Vol 52 (1) ◽  
pp. 8-16
Author(s):  
Jianping Jiang ◽  
Yuanyuan Zhang ◽  
Jianghua Chen ◽  
Xiaobing Yang ◽  
Changlin Mei ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Positive Association ◽  
Maintenance Hemodialysis ◽  
Advanced Glycation ◽  
Risk Of Mortality ◽  
Dialysis Vintage ◽  
Glycation End Products ◽  
End Products ◽  
All Cause Mortality ◽  
Cvd Mortality

Background: The relation of tissue and circulating advanced glycation end products (AGEs) with mortality in hemodialysis (HD) patients remains inconclusive. We aimed to investigate the association of serum AGEs (CML) and tissue AGEs estimated by skin autofluorescence (SAF) with all-cause and cardiovascular disease (CVD) mortality, and examine the possible modifiers for the association in HD patients with by far the largest sample size in any similar studies. Methods: A total of 1,634 HD patients were included from the China Cooperative Study on Dialysis (CCSD), a multicenter prospective cohort study. The primary and secondary outcomes were all-cause mortality and CVD mortality, respectively. Results: The median follow-up duration was 5.2 years. Overall, there was a positive relation of baseline SAF levels with the risk of all-cause mortality (per 1 AU increment, adjusted hazard ratio (HR), 1.30; 95% confidence interval (CI): 1.12, 1.50) and CVD mortality (per 1 AU increment, adjusted HR, 1.36; 95% CI: 1.14, 1.62). Moreover, a stronger positive association between baseline SAF (per 1 AU increment) and all-cause mortality was found in participants with shorter dialysis vintage, or lower C-reactive protein levels (Both p interactions <0.05). Nevertheless, there was no significant association between serum CML and the risk of mortality. Conclusions: In patients undergoing long-term HD, baseline SAF, but not serum CML, was significantly associated with the risk of all-cause and CVD death.

Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients Under Maintenance Hemodialysis

2015 ◽  
Vol 40 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Yu Zhang ◽  
Chang-Lin Mei ◽  
Shu Rong ◽  
Yuan-Yuan Liu ◽  
Guan-Qing Xiao ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Uremic Toxins ◽  
Maintenance Hemodialysis ◽  
Advanced Glycation ◽  
Tnf Α ◽  
Glycation End Products ◽  
End Products ◽  
Group 2 ◽  
End Stage ◽  
Group 1

Advanced glycation end products (AGEs) are protein-bound uremic toxins and are elevated in patients with the end-stage of renal disease. The present study sought to develop an effective method to remove the circulating AGEs from patients using the combination of hemodialysis (HD) and hemoperfusion (HP). Thirty-six patients undergoing maintenance HD for 3 months were randomly divided into two groups. Patients in Group 1 received HD, followed by the combined HP + HD treatment once, whereas patients in Group 2 were first treated with HP + HD and then they received the HD treatment alone. Patients treated with HD alone did not alter higher levels of serum AGEs. In contrast, patients treated with the combined HP + HD exhibited significantly lower levels of serum AGEs and TNF-α. Results from this study demonstrate that the combination of HD + HP treatment may be an effective and better approach to remove the protein-bound uremic toxins and inflammatory cytokines.

Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans

Metabolism ◽  
2006 ◽  
Vol 55 (7) ◽  
pp. 912-917 ◽  
Author(s):  
Mika Enomoto ◽  
Hisashi Adachi ◽  
Sho-ichi Yamagishi ◽  
Masayoshi Takeuchi ◽  
Kumiko Furuki ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Positive Association ◽  
Serum Levels ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Dietary Intake of Advanced Glycation End Products (AGEs) and Mortality Among Individuals with Colorectal Cancer

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4435
Author(s):  
Ziling Mao ◽  
Elom K. Aglago ◽  
Zhiwei Zhao ◽  
Casper Schalkwijk ◽  
Li Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dietary Intake ◽  
Advanced Glycation End Products ◽  
Dietary Intakes ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
All Cause Mortality ◽  
Specific Mortality

Advanced glycation end-products (AGEs) may promote oxidative stress and inflammation and have been linked to multiple chronic diseases, including cancer. However, the association of AGEs with mortality after colorectal cancer (CRC) diagnosis has not been previously investigated. Multivariable Cox proportional hazards models were used to calculate hazard ratios and corresponding 95% confidence intervals for associations between dietary intake of AGEs with CRC-specific and all-cause mortality among 5801 participant cases diagnosed with CRC in the European Prospective Investigation into Cancer and Nutrition study between 1993 and 2013. Dietary intakes of AGEs were estimated using country-specific dietary questionnaires, linked to an AGE database, that accounted for food preparation and processing. During a median of 58 months of follow-up, 2421 cases died (1841 from CRC). Individually or combined, dietary intakes of AGEs were not associated with all-cause and CRC-specific mortality among cases. However, there was a suggestion for a positive association between AGEs and all-cause or CRC-specific mortality among CRC cases without type II diabetes (all-cause, Pinteraction = 0.05) and CRC cases with the longest follow-up between recruitment and cancer diagnosis (CRC-specific, Pinteraction = 0.003; all-cause, Pinteraction = 0.01). Our study suggests that pre-diagnostic dietary intakes of AGEs were not associated with CRC-specific or all-cause mortality among CRC patients. Further investigations using biomarkers of AGEs and stratifying by sex, diabetes status, and timing of exposure to AGEs are warranted.

Sign in / Sign up

Export Citation Format

Share Document